Enalapril Maleate Tablet
Product Images NDC 23155-705
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Enalapril Maleate (NDC 23155-705). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 02
This appears to be a table organized in rows and columns showing the incidence of adverse effects in patients taking Enatapril versus Placebo. The adverse effects are grouped by body system including the body as a whole, cardiovascular, digestive, nervous-psychiatric, respiratory, skin, and urogenital. The table also shows the number of discontinuations due to each adverse effect.*
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 03
This text appears to be a table or chart indicating initial doses of creatinine to administer depending on the patient's renal status and clearance. It also mentions adjusting dosage on nondialysis days based on blood pressure response. There is a warning about anaphylactoid reactions during membrane exposure. Additionally, there is a specific dosage recommendation for dialysis patients.*
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 04
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 05
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 06
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 07
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 08
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 09
37366051 Ccb9 4ce6 9060 0d4fa9e00a66 10
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.